Rocket Pharmaceuticals, Inc.RCKTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +4.49% | +17.68% | +18.43% | +18.49% | +13.94% |
| Weighted Average Shares Diluted Growth | +4.49% | +17.68% | +18.43% | +18.49% | +13.94% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -6.82% | -5.68% | -5.70% | -6.52% | -37.38% |
| Book Value per Share Growth | -10.00% | -20.68% | -22.24% | -19.73% | -47.48% |
| Debt Growth | +1.82% | -2.30% | -2.31% | -2.33% | -2.44% |
| R&D Expense Growth | -10.51% | -17.87% | -4.76% | -19.49% | -21.44% |
| SG&A Expenses Growth | +17.65% | +33.17% | -5.87% | -32.31% | -42.05% |